---
layout: default
title: Vismodegib
parent: AI Predictions (L5)
nav_order: 648
evidence_level: L5
indication_count: 10
---

# Vismodegib
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Vismodegib: From Basal Cell Carcinoma to Medulloblastoma with Extensive Nodularity

## One-Sentence Summary

Vismodegib is a Smoothened (SMO) inhibitor that blocks the Hedgehog (Hh) signaling pathway, historically established as a treatment for basal cell carcinoma (BCC). The TxGNN model predicts it may be effective for **Medulloblastoma with Extensive Nodularity (MBEN)**, a rare SHH-pathway-driven pediatric brain tumor subtype, but this direction is currently supported by **no clinical trials** and **no published literature** — it rests solely on mechanistic plausibility.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Basal Cell Carcinoma (BCC) — no structured regulatory license data available for this drug; original indication inferred from literature evidence contained in this pack |
| Predicted New Indication | Medulloblastoma with Extensive Nodularity |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for Vismodegib is flagged as a data gap in this pack. However, the drug's rationale annotations consistently describe it as an SMO (Smoothened) inhibitor that blocks aberrant activation of the Sonic Hedgehog (SHH) signaling pathway — the same mechanism that made it a first-in-class agent for basal cell carcinoma, where uncontrolled Hh signaling drives tumor growth.

Medulloblastoma with Extensive Nodularity (MBEN) is a distinct histological subtype of medulloblastoma that is itself SHH-pathway-driven. Because Vismodegib's pharmacological target (SMO) sits directly within this pathway, the mechanistic overlap between its original indication and this new candidate indication is direct rather than incidental — both diseases arise from the same aberrantly activated signaling cascade. This explains the very high TxGNN score, which reflects strong biological plausibility rather than confirmed clinical benefit.

Notably, this same evidence pack independently scores "skin cancer" (an umbrella term encompassing BCC) as another high-ranking candidate, and that entry is backed by extensive Phase 2 trial data (including a 1,232-patient safety study) and European dermato-oncology guidelines. This cross-validation within the model's own outputs supports that the Hedgehog-pathway mechanism is real and clinically actionable — but for MBEN specifically, this mechanistic logic has not yet been tested in any registered trial or publication. Pediatric use also raises specific safety concerns (e.g., growth plate closure) that are unaddressed by any data in this pack.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (Hedgehog pathway / Smoothened [SMO] inhibitor) — not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |

## Safety Considerations

Please refer to the SmPC for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This prediction is at Evidence Level L5 — a pure model-generated hypothesis with no supporting clinical trials or literature. While the mechanistic link (shared SHH/SMO pathway biology with the drug's known BCC activity) is biologically plausible, there is no empirical evidence to justify moving beyond the hypothesis stage, and the target population (pediatric medulloblastoma) carries added safety complexity.

**To proceed, the following is needed:**
- Preclinical or early-phase clinical data specifically evaluating Vismodegib in SHH-driven medulloblastoma (MBEN subtype)
- Resolution of the blocking data gap on TFDA/EMA label warnings and contraindications (DG001), required before any safety pre-assessment
- Confirmed mechanism-of-action documentation from DrugBank (DG002)
- Pediatric-specific safety assessment, particularly regarding growth plate/bone development risks associated with Hedgehog pathway inhibition in children
- Regulatory status confirmation, since this pack currently shows no EU marketing authorization for this drug
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

